View the full directory of HCI Cancer Center members
A. Welm Lab
Our research focuses on better understanding the tumor-host interactions that facilitate metastasis, with the ultimate goal of discovering new, improved cancer therapies.
- Agarwal Group
- Akerley Group
- Andtbacka Group
- Angus-Hill Lab
The Atanackovic lab focuses on harnessing the human immune system for the fight against cancer, in particular hematologic malignancies such as MM.
The Ayer lab is interested in the transcriptional control of cellular proliferation and how these controls are subverted in human malignancy.
The primary focus of our laboratory's research is examining how cells modulate their behavior in response to both extrinsic and intrinsic signals. This process of signal integration has profound effects on cell migration, morphology, and function—behaviors that, when aberrant, can lead to cancer and other diseases.
- Beck Group
- Bernard Lab
The Bhaskara Lab studies Epigenetics, DNA damage response, DNA repair, DNA replication and chromatin structure.
- Boucher Group
- Bronner Group
Bryan Welm Lab
Our lab is focused on understanding both the normal processes regulating cell fate determination in the breast, and the relationship between cellular differentiation and cancer, in order to discover the complex molecular pathways driving this disease.
- Burt-Neklason Lab
We are interested in the molecular logic of totipotency—the ability of germ line stem cells and early embryos to become any type of cell. Within this broad and important question, we focus on how chromatin structure and epigenetics helps regulate gene transcription in the germ line and early embryos. We also examine how chromatin/epigenetics is misregulated in cancers.
The main focus of research in the Camp Lab is the identification of germ-line genetic variants that increase susceptibility to disease, with specific interests in breast cancer, chronic lymphocytic leukemia (CLL) and multiple myeloma (MM).
- Cannon-Albright Group
- Chandrasekharan Lab
- Curtin Group
Our lab's research program focuses on the biology of myeloproliferative neoplasms and the development of molecularly targeted therapies.
Michael W. Deininger, MD, PhD, & Thomas O’Hare, PhD
- Doherty Group
Our research focuses on the mechanisms that control cell growth and proliferation in the fruit fly, Drosophila melanogaster.
- Elizabeth Raetz
In spite of decades of research, there are few treatment advances for leukemia and lymphomas patients. These life-threatening diseases of the bone marrow are defined by the build up of leukemia cells and failure of normal blood cell development (hematopoiesis).
The overarching goal of the Evason laboratory is to investigate mechanisms involved in liver tumorigenesis in order to develop improved therapies to treat this deadly cancer.
- Factor Group
- Fluchel Group
Our team looks at control and response in mycosis fungoides patients and in patients treated in the post-autologous stem cell transplant setting.
- Gaffney Team
Gertz Lab Research
The Gertz Lab develops and applies experimental methods that take advantage of next-generation sequencing to create high-resolution maps of gene regulatory networks.
- Graves Lab
- Grossman Lab
Our research is focused on the molecular and global epidemiology of cancers of the head and neck, thyroid, endometrium, ovary, lung, testis, and colorectum.
The Holmen Lab is focused on defining critical targets in cancer cells that can become the focus for therapeutic intervention.
- Hu Group
Jared Rutter Lab
Using both broad and deep approaches, our goal is to define the molecules and their interactions that enable robust and responsive cellular metabolic control.
- Jensen Group
KB Jones Lab
The K. B. Jones Lab is directed by and supports Dr. Jones as he provides care to patients of all ages with bone and soft-tissue sarcomas, performing surgery to remove the cancers and reconstruct the limbs or body wall.
- Kepka Group
Kirchhoff Research Group
The Kirchhoff Research Group has a collective goal of understanding and improving the health of pediatric, adolescent, and young adult cancer survivors.
- Leachman Lab
- Lowrance Group
Research in the McMahon Lab focuses on the importance of RAS effectors, such as the RAF family of protein kinases and phosphoinositide 3’ (PI3’)-kinases in the aberrant physiology of cancer cells.
The Mendoza Lab is using recent advances in proteomics and quantitative imaging to understand how extracellular signals impinge on cytoskeletal dynamics and how oncogenic pathway hyperactivation impacts cancer invasion.
The Oliver Lab focuses on mechanisms of drug response and resistance in lung cancer with the goal of improving treatment options for patients with lung cancer.
The Rosenblatt Lab studies both cell death and cell division and the roles that the actin and microtubule cytoskeletons play in both processes. Our lab investigates if epithelial extrusion could drive cell death in order to control cell numbers, and whether this process malfunctions in cancer.
- Rupper Group
- SARC Lab
The Schiffman Lab studies pediatric hereditary cancer syndromes, with a special interest in genetic susceptibility to childhood cancers.
- Smith Group
- Snyder Lab
In the Spike Lab, we are interested in questions at the intersection of stem cells, development, and cancer.
Our laboratory is interested in how genetic programs governing embryonic development are exploited during cancer initiation and progression.
Research in the Tavtigian Lab concentrates on two areas of genetic susceptibility to cancer: 1) Identification and characterization of intermediate-risk and high-risk cancer susceptibility genes, and 2) analysis of unclassified variants that are observed during the clinical testing of established high-risk cancer susceptibility genes.
The Ullman Lab studies the coordination of cell division, with a particular focus on how assembly of nuclear architecture is integrated with other events of cell division.
The VanBrocklin Lab is interested in identifying novel molecular targets vital for tumor growth and progression and validating these candidates in pre-clinical models in order to develop rational pharmacological intervention strategies for melanoma and NSCLC patients
Our projects involve the development of new molecular methods and bioinformatics approaches to explore the cancer genome and translate our discoveries into clinical tools that improve patient care.
- Wu Group